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patient charts were identified (mean age: 41.2yrs; female:67%; currently treated 
with DMTs: 601(85%); discontinued DMTs in past 3 months: 35(5%); DMT-naive: 
35(10%). Of the 601 currently treated patients, current line of DMT: 1st-line-62%, 
2nd-line-28%, > = 3rd-line-10%. 1st-line patient characteristics included- mean 
age:40.0yrs; female:69%; average time-to-initiation of DMT from diagnosis:7.5mo; 
time on current 1st-line DMT:51.5months; JCV status: positive-1%/negative-7%/
don’t know-8%/not tested-84%. Top-4 reason for 1st-line DMT initiation: efficacy 
against relapses(25%), efficacy in early MS(25%), efficacy in slowing disease pro-
gression(18%), patient decision(12%). Mean EDSS-score:1.65; current disability (per-
physician-judgment): mild-81%/moderate-17%/severe-2.2%. 2nd-line DMT patient 
characteristics included- mean age:42.8yrs; female:66%; average time-to-initiation 
of DMT from diagnosis:3.7mo; time on current 2nd-line DMT:31.2months; JCV status: 
positive-14%/negative-26%/don’t know-8%/not tested-52%. Top-4 reason for choos-
ing the 2nd-line DMT: efficacy against relapses(34%), efficacy in slowing disease pro-
gression(34%), patient decision(8%), tolerability(7%); correspondingly, top-4 reasons 
for switch from 1st-line DMTs were: lack of efficacy(38%), relapse(24%), flu-like symp-
toms(17%), injection-site reactions(11%). Mean EDSS-score:2.98; current disability 
(per-physician-judgment): mild-50%/moderate-44%/severe-7%. ConClusions: In 
this cohort, RRMS patients on 2nd-line DMT appear to have higher disease burden 
compared to those on 1st-line DMT. Time-to-initiation of first DMT after diagnosis 
differed significantly between these two groups. Further research is warranted to 
scrutinize the observed treatment patterns and treatment sequencing strategies 
to alleviate patient burden.
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objeCtives: Due to a rapidly aging population, age-related diseases, such as 
Alzheimer’s disease (AD), are becoming a great concern in China. The objective of 
this study was to provide an overview of the future socio-economic issues raised by 
the increasing prevalence of AD in China. Methods: A literature review was done 
to collect information on the disease management, the demographic projections, 
and medical capabilities available in China. To answer the questions that emerged 
from the literature review, five clinical experts and two hospital administrative 
payers were interviewed. Results: It was estimated that there were 10 million 
cases of AD in China in 2010. As a typical aging disease, the burden of AD in China 
is substantial and will continue growing as the elderly population grows. Around 
33% of the Chinese population is expected to be older than 60 in 2050, representing 
438 million people. A large imbalance was found between AD management needs 
and availability of health care services for AD patients, as a result of: 1> Chinese 
culture values family care for the elderly, while the single-child policy resulting 
in 4 grand-parents and 2 parents being cared for by one child, 2> extremely poor 
awareness of AD in China both publicly and privately (assimilated as dementia), and 
3> limited medical capabilities for AD. As a result, it is predicted that working-age 
Chinese population will have to take time to provide informal care for the elderly, 
leading to an important impact on the productivity. ConClusions: Results suggest 
China is an emerging market for AD treatments. There is a large imbalance between 
AD management needs and capabilities to provide it in China.
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objeCtives: The Brazilian public health system (SUS) provides donepezil, rivastig-
mine and galantamine for all individuals with Alzheimer’s disease (AD). The Ministry 
of Health (MoH) is responsible for the acquisition of rivastigmine and donepezil, 
whereas the States are responsible for the acquisition of galantamine, reimbursed 
by MoH. The aim of this study is to characterize patients with AD and the financial 
resources employed by the MoH. Methods: Descriptive analysis of the profile of 
patients and drug expenses, based on data about the amount dispensed and values 
reimbursed by the MoH in 2012, avaliable in the database of the SUS (current values; 
exchange rate: US$ 1 = R$ 2.36). Were considered: a) MoH expenses with central 
acquisition of donepezil and rivastigmine and b) values of galantamine reimburse-
ment. Results: In 2012, 119,378 patients with AD were treated with medicines in 
the SUS. These patients had a mean age of 78.57 years and 65.87% were women. Most 
of them was treated with rivastigmine (42.98%), followed by donepezil (39.07%) and 
galantamine (17.95%). The annual costs per patient with galantamine were 17 times 
higher than donepezil (US$ 1,045.07 with galantamine, US$ 439.78 with rivastigmine 
and US$ 61.47 with donepezil). The MoH expenses in this period with these drugs 
summed up to US$ 14,176,227.12. This amount represented 0.73% of the total MoH´s 
budget of high-cost drugs in 2012. The biggest expenses occurred with rivastigmine 
(76.16%), followed by donepezil (12.09%) and galantamine (11.74%). ConClusions: 
Despite the higher cost of treatment with galantamine, the impact with rivastigmine 
was greater because it is the most common drug. The central acquisition of drugs 
results in lower treatment cost due to its scale economy and the public development 
partnerships results, a strategy aimed to strengthen the health industrial complex, 
the resource optimization and the access to medicines.
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drug treatment treatment, polytherapy, low mean seizure free interval, male gen-
der, presence of ADR and high mean duration of disease are significantly (P < 0.05) 
associated with low HRQoL scores. ConClusions: Epilepsy has a negative impact 
on their HRQoL. The determinants found by this study will help in framing different 
strategies to improve patient’s compliance and their HRQoL.
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objeCtives: Little evidence exists on the impact of herpes zoster (HZ ) on qual-
ity of life (QoL) and work absenteeism for immunocompromised patients. This 
study describes work absenteeism, and loss in quality of life due to HZ among 
immunocompromised individuals in the United States, UK, Canada, France and 
Germany. Methods: A web-based survey was conducted with adult males and 
females who: 1) had cancer or stem cell transplant (SCT) and HZ (HZ and cancer 
group); 2) cancer or SCT without HZ (cancer group); and 3) had neither cancer, SCT or 
HZ (immunocompetent group). Validated measures included the Brief Pain Inventory 
(BPI), activities of daily living (ADL), the EQ-5D-5L, and the World Health Organization 
Health and Work Performance Questionnaire (WHO HPQ) for work absenteeism. 
Multivariable logistic regressions controlling for demographic characteristics and 
comorbidities examined the impact of HZ on the EQ-5D-5L score and absenteeism 
relative to the cancer and immunocompetent groups. Results: Overall, there were 
353 respondents with HZ (HZ and cancer group), 351 with cancer only, and 353 
were immunocompetent. HZ patients had average pain scores that were at least 
2 and 3 points greater (p< 0.001) than the cancer and immunocompetent groups, 
respectively. Across all ADLs, HZ patients scored 4 and 5 points higher (p< 0.001) 
than the cancer and immunocompetent groups, respectively. HZ patients had 2 
and 20 more hours of absenteeism than the cancer and immunocompetent (p= 0.06) 
groups; and scored 0.5 and 7.3 points lower on the EQ-5D-5L than the cancer and 
immunocompetent (p= 0.01) groups. ConClusions: HZ respondents had greater 
pain, more absenteeism and lower EQ-5D-5L scores than those without HZ. Despite 
the differences between the HZ and cancer groups on ADLs and pain, these groups 
reported similar scores on the EQ-5D-5L, suggesting the EQ-5D-5L may not be sensi-
tive enough to capture the impact of HZ.
NeuroloGiCal DisorDers – health Care use & Policy studies
PND50
TriPTaN use aND assoCiaTeD healTh Care uTilizaTioN aND CosTs iN 
aDulTs wiTh MiGraiNes
Noxon V.1, Lu K.1, Wu J.2
1South Carolina College of Pharmacy – USC Campus, Columbia, SC, USA, 2University of South 
Carolina, Greenville, SC, USA
objeCtives: Triptans have been used widely as acute treatments for migraine. 
This study aimed to determine distinct characteristics of triptan users and non-
users, identify socioeconomic-related factors associated with triptan use, define 
migraine utilization patterns and ascertain differences in cost between triptan and 
non triptan users in migraine patients. Methods: This study used the Medical 
Expenditure Panel Survey (MEPS) household component files for panels 11-14 (years 
2006-2010). Subjects who had a migraine diagnosis and were 18 years or older were 
included in the sample. Triptan users were identified from prescribed medicines 
files. Predictors associated with triptan use in migraineurs were assessed by mul-
tivariate logistic regression. Health care expenses (per person per year) including 
medical care and prescription drug expenses were measured from the payer per-
spective. The association between health expenses and triptan use was examined by 
multivariate linear regression. Results: We identified 1,644 eligible subjects in our 
study, representing 36.7 million individuals during 2006-2010 in the United States. 
Nearly 30% of the subjects received triptans to treat migraine. The triptan users 
were more likely to be women, white and have college degrees than non-users. The 
subjects receiving triptans had higher total numbers of office visits and prescription 
drug fills but lower number of emergency department visits than those not. The 
triptan expense accounted for 47% of migraine-related expenses in one year. After 
adjustment, triptan users showed 26% higher total all-cause health care expenses 
than non-users. ConClusions: Socioeconomic factors such as gender, race, educa-
tion and income levels might influence triptan use in migraineurs. Triptan treatment 
impacts on migraine-related expenses and is associated with increased total health 
care expenses in subjects with migraine.
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objeCtives: To assess treatment dynamics and disease burden among RRMS 
patients currently treated with DMTs in the US. Methods: A multi-center medi-
cal chart-review study of MS patients was conducted in 4Q2012 among neurologists 
to collect de-identified data. Neurologists were screened for duration of practice 
(> = 3yrs) and patient volume (> = 15 MS patients/month) and recruited from a large 
panel to be geographically representative of the US. Medical charts of next 10 con-
secutive MS patients were abstracted by each neurologist to collect patient diag-
nosis, treatment patterns and symptomatology/disability-status. RRMS patients 
currently treated with 1st-line & 2nd-line DMTs were evaluated. Results: 708 RRMS 
